Viatris VTRS Generics — Net Sales

Other product segments

Similar metrics at other companies

ANIPGenerics and Other — Net Revenues

$109.22M+6.0%

ANIPGenerics and Other total net revenues — Net Revenues

$109.22M+6.0%

ANIPGeneric pharmaceutical products — Net Revenues

$105.4M+6.8%

ANIPOther generic revenues — Net Revenues

$3.82M-12.5%

BLCOBranded and Other Generics — Total revenues

$49M-9.3%

MIRMProduct sales, net — Product sales, net

$159.88M+43.3%

Questions, answered.

What is Viatris's generics — net sales?

Viatris (VTRS) reported generics — net sales of $1.18B in Q1 2026.

How has Viatris's generics — net sales changed year-over-year?

Viatris's generics — net sales increased by 4.5% year-over-year, from $1.13B to $1.18B.

What is the long-term trend for Viatris's generics — net sales?

Over 4 years (2021 to 2025), Viatris's generics — net sales has grown at a -7.7% compound annual growth rate (CAGR), from $6.97B to $5.07B.

What does generics — net sales mean?

This metric represents the total revenue generated from the sale of generic pharmaceutical products, including both commoditized and complex generics. It reflects the company's ability to capture market share in the off-patent drug space and serves as a primary indicator of the segment's competitive positioning and pricing power. This revenue stream is critical for assessing the company's volume-based growth strategy within the global pharmaceutical market.